CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1204-1208

  Alvarez, Enrique ^a   Piccio, Laura ^a   Mikesell, Robert J ^a   Klawiter, Eric C ^a,b   Parks, Becky J ^a   Naismith, Robert T ^a   Cross, Anne H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarker; CXCL13; Multiple sclerosis; myelin basic protein; neurofilament; neuroinflammation; neuromyelitis optica

Indexed keywords

CXCL13 CHEMOKINE; NEUROFILAMENT PROTEIN; OLIGOCLONAL BAND;

ADULT; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

BIOMARKER; CXCL13; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; NEUROFILAMENT; NEUROINFLAMMATION; NEUROMYELITIS OPTICA;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84879881949     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512473362     Document Type: Article

References (10)

1. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006 ; 129: 200-211
2. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler. 2011 ; 17: 335-343
3. Zhong X, Wang H, Dai Y, et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2011 ; 240-241: 104-108
4. Schmidt C, Plate A, Angele B, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011 ; 76: 1051-1058
5. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology. 2010 ; 75: 208-216
6. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
7. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology. 2010 ; 74: 1860-1867
8. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008 ; 65: 1443-1448
9. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
10. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain. 2007 ; 130: 1235-1243